The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation

Contraception

Volumn 75, Issue 5, 2007, Pages 344-354

  Dinger, Jürgen C ^a   Heinemann, Lothar A J ^a   Kühl Habich, Dörthe ^b  

^a Berlin Center for Epidemiology and Health Research   (Germany)

^b Systems Research (EPES)   (Germany)

Author keywords

Adverse events; Drospirenone; EURAS; Oral contraceptives; VTE

Indexed keywords

DROSPIRENONE; GESTAGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HEALTH SURVEY; HEART ARRHYTHMIA; HUMAN; INCIDENCE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; QUESTIONNAIRE; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; ARRHYTHMIA; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; MORTALITY; THROMBOEMBOLISM;

EID: 34047263992     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.12.019     Document Type: Article

References (32)

1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346 (1995) 1582-1588
2. Jick H., Jick S.S., Gurewich V., Myers M.W., and Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346 (1995) 1589-1593
3. Spitzer W.O., Lewis M.A., Heinemann L.A., Thorogood M., and MacRae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312 (1996) 83-88
4. Bloemenkamp K.W., Rosendaal F.R., Helmerhorst F.M., Buller H.R., and Vandenbroucke J.P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346 (1995) 1593-1596
5. Kemmeren J.M., Algra A., and Grobbee D.E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 323 (2001) 131-134
6. Heinemann L.A., Lewis M.A., Assmann A., and Thiel C. Case control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use. Contraception 65 (2002) 207-214
7. Preston R.A., Alonso A., Panzitta D., Zhang P., and Karara A.H. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 15 (2002) 816-822
8. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62 (2000) 29-38
9. Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric 6 Suppl 3 (2003) 49-54
10. Schürmann R., Holler T., and Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regime. Climacteric 7 (2004) 189-196
11. Warming L., Ravn P., Nielsen T., and Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric 7 (2004) 103-111
12. Heinemann L.A., and Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf 27 13 (2004) 1001-1018
13. Crosignani P.G., and La Vecchia C. Concordant and discordant effects on cardiovascular risks exerted by oestrogen and progestogen in women using oral contraception and hormone replacement therapy. ESHRE Capri Workshop Group. Hum Reprod Update 5 (1999) 681-687
14. Suissa S., Blais L., Spitzer W.O., Cusson J., Lewis M., and Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 56 (1997) 141-146
15. Heinemann L.A. The changing scene: an unnecessary pill crisis. Hum Reprod Update 5 (1999) 746-755
16. Lewis M.A., MacRae K.D., Kuhl-Habich D., Bruppacher R., Heinemann A.J., and Spitzer W.O. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 14 (1999) 1493-1499
17. Lewis M.A. The Transnational Study on Oral Contraceptives and the Health of Young Women: methods, results, new analyses and the healthy user effect. Hum Reprod Update 5 (1999) 707-720
18. Heinemann L.A., Garbe E., Farmer R., and Lewis M.A. Venous thromboembolism and oral contraceptive use: a methodological study of diagnostic suspicion and referral bias. Eur J Contracept Reprod Health Care 5 (2000) 183-191
19. European Agency for the Evaluation of Medicinal Products. Combined oral contraceptives and venous thromboembolism. The European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products (CPMP) public assessment report. London, 28 September 2001. [online]. Available from URL (2001). http://www.emea.eu.int/pdfs/human/regaffair/0220101en.pdf [Accessed Oct. 30, 2006]
20. Heinemann L.A., and Dinger J.C. Range of published estimates of VTE incidence in young women. Contraception 75 (2007) 328-336
21. Scurr J.H., Machin S.J., Bailey-King S., Mackie I.J., McDonald S., and Smith P.D.C. Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial. Lancet 357 (2001) 1485-1489
22. Belcaro C., Geroulakos G., Nicolaides A.N., Myers K.A., and Winford M. Venous thromboembolism from air travel: the LONFLIT Study. Angiology 52 (2001) 369-374
23. Schwarz T., Siegert G., Oettler W., et al. Venous thrombosis following long-haul flights. Arch Intern Med 163 (2003) 2759-2764
24. Potthoff P., Heinemann L.A.J., and Güther B. A household panel as a tool for cost-effective health-related population surveys: validity of the "Healthcare Access Panel". Ger Med Sci 2 (2004). Doc05/20040716. Available from URL www.egms.de/pdf/gms/2004-2/000015.pdf [Accessed Oct. 30, 2006]
25. Güther B. Access panel - quality aspects and experience. In: Streich W., Braun B., and Helmert U. (Eds). Surveys in public health - developments and perspectives in research and political counseling (2005), Asgard Verlag, Sankt Augustin 91-102
26. Potthoff P., and Güther B. Access panel in the context of health research. Forum Public Health 13 (2005) 16
27. Grady W.R., Hayward M.D., and Yagi J. Contraceptive failure in the United States: estimates from the 1982 National Survey of Family Growth. Fam Plann Perspect 18 (1986) 200-209
28. Jones E.F., and Forrest J.D. Contraceptive failure rates based on the 1988 NSFG. Fam Plann Perspect 24 (1992) 12-19
29. Fu H., Darroch J.E., Haas T., and Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect 31 (1999) 56-563
30. Harrison-Woolrych M., Ashton J., and Coulter D. Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported?. Contraception 67 (2003) 53-56
31. Danish Health Registers. [online]. Available from URL. http://www.laegemiddelstyrelsen.dk [Accessed Oct. 28, 2006]
32. Federal Statistical Office. Statistical yearbook 2006 for the Federal Republic of Germany (2006), Statistisches Bundesamt, Wiesbaden 54